NATICK, Mass. and SAN FRANCISCO, Sept. Twenty five (HSMN NewsFeed) — Boston Scientific Corporation (NYSE: BSX ) today announced two-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant s…
Devices, Interventional Cardiology
Boston Scientific, HORIZONS-AMI, TAXUS Express2, drug eluting stent

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents Compared to Bare-Metal Stents in Heart Attack Patients at Two Years”
Leave a Comment